DAXX and neuroendocrine carcinoma: More recently, in 2019, the WHO updated the classification of NETs based on their molecular differences: well-differentiated NETs are defined by mutations in MEN1, DAXX, and ATRX, whereas neuroendocrine carcinomas usually have TP53 or RB1 mutations.